Syed Muhammad Jawad Zaidi, Rabia Muhammad Wali, Naila Inayat, Sadia Anjum
{"title":"Clinical Outcomes and Long-Term Effects of Consolidative Radiotherapy in Paediatric Hodgkin's Lymphoma.","authors":"Syed Muhammad Jawad Zaidi, Rabia Muhammad Wali, Naila Inayat, Sadia Anjum","doi":"10.29271/jcpsp.2025.06.778","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the long-term effects and disease outcomes of consolidative radiotherapy in paediatric Hodgkin's lymphoma (PHL).</p><p><strong>Study design: </strong>Descriptive study. Place and Duration of the Study: Department of Paediatric Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan, from March to November, 2023.</p><p><strong>Methodology: </strong>This retrospective cohort study was conducted on 91 PHL patients. All patients with the presence of residual disease on interim PET scan received radiation therapy. A standard dose of 19.8 Gy was given as 11 fractions, and boost was given to bulky disease as 10 Gy in 5 fractions. Data regarding patient demographics, disease characteristics, and treatment details were collected from the institutional database.</p><p><strong>Results: </strong>Out of the 91 patients, 73 (80.2%) were male and 18 (19.8%) were female. The overall mean age at presentation was 7.7 ± 3.3 years. High-risk disease was found in 81 (89%), while 44 (48.4%) had stage IV disease. Complete remission was achieved in 70 (76.9%), loss to follow-up in 11 (12.1%), disease progression/relapse in 4 (4.4%), and death during treatment in 6 (6.6%) patients. The five-year overall survival was 90%, and event-free survival was 76.9%. During treatment, a total of nine patients had moderate-to- severe left ventricular dysfunction, six patients had altered thyroid profiles (hypothyroidism), three developed pulmonary fibrosis, and one patient developed cerebellar ataxia.</p><p><strong>Conclusion: </strong>There is a good five-year overall and event-free survival. Cardio toxicity, hypothyroidism, and pulmonary fibrosis were common long-term chemotherapy / radiotherapy-related side effects. Prospective randomised controlled trial is needed to reduce dose of radiotherapy by giving it to PET-positive residual disease at the end of treatment rather than at mid-assessment.</p><p><strong>Key words: </strong>Paediatric Hodgkin's lymphoma, Radiotherapy, Clinical outcomes.</p>","PeriodicalId":94116,"journal":{"name":"Journal of the College of Physicians and Surgeons--Pakistan : JCPSP","volume":"35 6","pages":"778-783"},"PeriodicalIF":0.8000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the College of Physicians and Surgeons--Pakistan : JCPSP","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29271/jcpsp.2025.06.778","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To evaluate the long-term effects and disease outcomes of consolidative radiotherapy in paediatric Hodgkin's lymphoma (PHL).
Study design: Descriptive study. Place and Duration of the Study: Department of Paediatric Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan, from March to November, 2023.
Methodology: This retrospective cohort study was conducted on 91 PHL patients. All patients with the presence of residual disease on interim PET scan received radiation therapy. A standard dose of 19.8 Gy was given as 11 fractions, and boost was given to bulky disease as 10 Gy in 5 fractions. Data regarding patient demographics, disease characteristics, and treatment details were collected from the institutional database.
Results: Out of the 91 patients, 73 (80.2%) were male and 18 (19.8%) were female. The overall mean age at presentation was 7.7 ± 3.3 years. High-risk disease was found in 81 (89%), while 44 (48.4%) had stage IV disease. Complete remission was achieved in 70 (76.9%), loss to follow-up in 11 (12.1%), disease progression/relapse in 4 (4.4%), and death during treatment in 6 (6.6%) patients. The five-year overall survival was 90%, and event-free survival was 76.9%. During treatment, a total of nine patients had moderate-to- severe left ventricular dysfunction, six patients had altered thyroid profiles (hypothyroidism), three developed pulmonary fibrosis, and one patient developed cerebellar ataxia.
Conclusion: There is a good five-year overall and event-free survival. Cardio toxicity, hypothyroidism, and pulmonary fibrosis were common long-term chemotherapy / radiotherapy-related side effects. Prospective randomised controlled trial is needed to reduce dose of radiotherapy by giving it to PET-positive residual disease at the end of treatment rather than at mid-assessment.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
